Judy Maddox

5.8k total citations · 3 hit papers
19 papers, 3.7k citations indexed

About

Judy Maddox is a scholar working on Oncology, Molecular Biology and Orthopedics and Sports Medicine. According to data from OpenAlex, Judy Maddox has authored 19 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Orthopedics and Sports Medicine. Recurrent topics in Judy Maddox's work include Bone health and treatments (12 papers), Bone Metabolism and Diseases (11 papers) and Bone health and osteoporosis research (10 papers). Judy Maddox is often cited by papers focused on Bone health and treatments (12 papers), Bone Metabolism and Diseases (11 papers) and Bone health and osteoporosis research (10 papers). Judy Maddox collaborates with scholars based in United States, Belgium and Canada. Judy Maddox's co-authors include Andreas Grauer, Paul Meisner, Cesar Libanati, Michelle Fan, Akimitsu Miyauchi, Jeffrey Petersen, Andrew C. Karaplis, Thierry Thomas, Mattias Lorentzon and Kenneth G. Saag and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Judy Maddox

19 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

2016 1.1k citations Felicia Cosman, Daria B. Crittenden et al. New England Journal of Medicine profile →
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

2017 942 citations Kenneth G. Saag, Jeffrey Petersen et al. New England Journal of Medicine profile →
Romosozumab in Postmenopausal Women with Low Bone Mineral Density

2014 886 citations Michael R. McClung, Andreas Grauer et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Judy Maddox

Since Specialization

Citations

This map shows the geographic impact of Judy Maddox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Maddox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Maddox more than expected).

Fields of papers citing papers by Judy Maddox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Maddox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Maddox. The network helps show where Judy Maddox may publish in the future.

Co-authorship network of co-authors of Judy Maddox

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Maddox. A scholar is included among the top collaborators of Judy Maddox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Maddox. Judy Maddox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab 2022 ·The Journal of Clinical Pharmacology ·Cheng‐Pang Hsu, Judy Maddox, Geoffrey A. Block, (unknown), Zhigang Yu	14
2	Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study 2021 ·Endocrinology and Metabolism ·Ki‐Hyun Baek, Yoon‐Sok Chung, (unknown), In Joo Kim, Kyoung Min Kim, (unknown), Ki Deok Park, Rajani Dinavahi, Judy Maddox, Wenjing Yang, (unknown), Sang Jin Lee, Hyung-Jin Cho, (unknown)	14
3	Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study 2020 ·Osteoporosis International ·Edith Lau, Rajani Dinavahi, Yu Cho Woo, Chih‐Hsing Wu, Jian‐Long Guan, Judy Maddox, (unknown), Wenjing Yang, Changsoo Shin	21
4	A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab 2020 ·Osteoporosis International ·Michael R. McClung, (unknown), Jacques P. Brown, Jean‐Yves Reginster, Bente Langdahl, Judy Maddox, Yifei Shi, Maria Rojeski, Paul Meisner, Andreas Grauer	35
5	A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures 2020 ·Journal of Bone and Joint Surgery ·Emil H. Schemitsch, Theodore Miclau, Theofilos Karachalios, Lauren L. Nowak, Parag Sancheti, Rudolf W. Poolman, John Caminis, Nadia Daizadeh, Ricardo E. Dent‐Acosta, Ogo Egbuna, Arkadi Chines, Judy Maddox, Andreas Grauer, Mohit Bhandari	60
6	Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension 2019 ·Archives of Osteoporosis ·Akimitsu Miyauchi, Rajani Dinavahi, Daria B. Crittenden, Wenjing Yang, Judy Maddox, (unknown), Yoichi Nakamura, Cesar Libanati, Andreas Grauer, (unknown)	36
7	Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab 2019 ·Osteoporosis International ·David L. Kendler, Henry G. Bone, Francesco Massari, Evelien Gielen, Santiago Palacios, Judy Maddox, Chao Yan, Susan Yue, Rajani Dinavahi, Cesar Libanati, Andreas Grauer	75
8	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study 2018 ·Journal of Bone and Mineral Research ·Michael R. McClung, Jacques P. Brown, Adolfo Díez‐Pérez, Heinrich Resch, John Caminis, Paul Meisner, Michael A. Bolognese, Stefan Goemaere, Henry G. Bone, José Zanchetta, Judy Maddox, Sarah Bray, Andreas Grauer	159
9	A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis 2018 ·The Journal of Clinical Endocrinology & Metabolism ·E. Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul Meisner, Paul D. Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, S. Horlait	201
10	Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study 2017 ·Bone ·Hideaki Ishibashi, Daria B. Crittenden, Akimitsu Miyauchi, Cesar Libanati, Judy Maddox, Michelle Fan, (unknown), Andreas Grauer	75
11	Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis breakdown → 2017 ·New England Journal of Medicine ·Kenneth G. Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C. Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul Meisner, Andreas Grauer	942
12	Romosozumab Treatment in Postmenopausal Women with Osteoporosis breakdown → 2016 ·New England Journal of Medicine ·Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi, Neil Binkley, E. J. Czerwiński, Serge Ferrari, Lorenz C. Hofbauer, Edith Lau, E. Michael Lewiecki, Akimitsu Miyauchi, Cristiano A. F. Zerbini, Cassandra E. Milmont, Li Chen, Judy Maddox, Paul Meisner, Cesar Libanati, Andreas Grauer	1131
13	Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study 2016 ·Bone Abstracts ·(unknown), Cesar Libanati, Daria B. Crittenden, Michael A. Bolognese, Jacques P. Brown, Nadia Daizadeh, Eva Dokoupilová, Klaus Engelke, Joel S. Finkelstein, H K Genant, Stefan Goemaere, (unknown), Esteban Jódar-Gimeno, Tony M. Keaveny, David L. Kendler, Péter L. Lakatos, Judy Maddox, Jorge Malouf, Francesco Massari, José Fernando Molina	6
14	OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density 2015 ·Annals of the Rheumatic Diseases ·Michael R. McClung, Arkadi Chines, Jacques P. Brown, Adolfo Díez‐Pérez, Heinrich Resch, John Caminis, (unknown), Stefan Goemaere, Henry G. Bone, J. R. Zanchetta, Judy Maddox, O. Rosen, Sarah Bray, Andreas Grauer	21
15	Romosozumab in Postmenopausal Women with Low Bone Mineral Density breakdown → 2014 ·New England Journal of Medicine ·Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone	886
16	OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results 2013 ·Annals of the Rheumatic Diseases ·Michael R. McClung, Andreas Grauer, Steven Boonen, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Leonid Katz, Judy Maddox, Yang Yu, Cesar Libanati, Henry G. Bone	5
17	Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. 2011 ·PubMed ·Alice B. Gottlieb, (unknown), Edward H. Giannini, Philip J. Mease, Juan Li, Yun Chon, Judy Maddox, Haoling H. Weng, Joseph Wajdula, (unknown), Scott W. Baumgartner	37
18	Temporal Small-Vessel Inflammation in Patients with Giant Cell Arteritis: Clinical Course and Preliminary Immunohistopathologic Characterization 2010 ·The Journal of Rheumatology ·Elise Belilos, Judy Maddox, (unknown), Jolanta Kowalewska, George K. Turi, Lucien E. Nochomovitz, (unknown), Steven E. Carsons	20
19	Combined modality treatment of lymphedema using the Reid Sleeve and the BioCompression/Optiflow System 2005 ·Journal of Clinical Oncology ·Andrea Hafner, Robert A. Robinson, (unknown), Judy Maddox, (unknown), (unknown), Thomas Reid	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact